If the mutation in patients does not concern the mutations above, then the programmed death ligand 1 (PD-L1) mutation maybe a better choice, but there are still some limits, for example, the mutation of PD-L1 at least appears 50% mutation in the lung cancer patients (38). This evidence concerns the gene CD274 and lung carcinoma.